In an effort to provide you with timely market feedback from ASCO 2014, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ from the meeting. This third report explored presentations in Melanoma.
Geographic Distribution of Respondents
Attendance at 2014 ASCO Annual Meeting
Survey Participants’ Melanoma Patient Flow: Averaged 45 Total Cases Each Quarter
* Survey Participants = Medical Oncologists with an identified clinical interest in melanoma
Impact of New Monoclonal Antibodies Targeting the PD-1/PD-1L Axis for Melanoma Immunotherapy Treatments
Forecasting the Integration of Immune Checkpoint Inhibitor Targeting PD-1/PD-1L Axis for Metastatic Melanoma Patients
Importance of Ipilimumab in the Adjuvant Setting for Metastatic Melanoma
Impact of the OPTIM Trial – T-VEC’s Effect on Unresectable Melanoma
Conclusions: Impact of ASCO 2014 on Clinical Practices for Melanoma
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, Sr. Director Medical Services and Strategy; Jessica Harnisch, Assoc. Global Medical Analyst; and Jan Heybroek, President MDoutlook.
You must be logged in to post a comment